Vaccines · 2025
Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022-December 2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nilasari Hanny, Miranda Eliza, Marissa Melani, Ruspitawati Ani, Handayani Dwi O T L, Salama Ngabila, Setiawan Budi, Supriadi, Aisyah Tiranti V, Inggariwati, Haq Arif S, Zuhroh Siti, Safitri Eka Y, Pramono Rahmat A, Wisnuwardani Inggrita, Nelwan Erni J, Sinto Robert, Susilo Adityo, Saharman Yulia R, Ratnoglik Suratno L, Pitawati Ni L P, Fauzan Muhammad, Hasanah Sekar S A, Sharasti Megandhita, Yunihastuti Evy
Аннотация
BACKGROUND/OBJECTIVE: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia.
METHODS: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV).
RESULTS: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART).
CONCLUSIONS: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
METHODS: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV).
RESULTS: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART).
CONCLUSIONS: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.